Stockscreener 앱 받기
56.58
6.17%
-3.72
시간 외 거래:
56.49
-0.09
-0.16%
전일 마감가:
$60.30
열려 있는:
$60.16
하루 거래량:
4.31M
Relative Volume:
1.98
시가총액:
$2.77B
수익:
순이익/손실:
$-192.89M
주가수익비율:
-14.52
EPS:
-3.8976
순현금흐름:
$-172.97M
1주 성능:
-16.72%
1개월 성능:
-31.48%
6개월 성능:
-54.83%
1년 성능:
+7.71%
1일 변동 폭
$53.54
$60.23
1주일 범위
$53.54
$67.52
52주 변동 폭
$49.80
$151.02
Celcuity Inc Stock (CELC) Company Profile
명칭
Celcuity Inc
전화
763-392-0767
주소
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
56.58 | 2.77B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-17 | 개시 | JP Morgan | Overweight |
| 2026-05-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-04-27 | 개시 | Citizens | Mkt Outperform |
| 2025-12-12 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Stifel | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-02-22 | 개시 | Stifel | Buy |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-08 | 개시 | Canaccord Genuity | Buy |
| 2021-09-07 | 개시 | Jefferies | Buy |
| 2021-07-29 | 개시 | Cowen | Outperform |
| 2021-07-27 | 개시 | Needham | Buy |
| 2021-01-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-11 | 재개 | Craig Hallum | Buy |
| 2018-11-20 | 개시 | H.C. Wainwright | Buy |
모두보기
Celcuity Inc 주식(CELC)의 최신 뉴스
New Strong Sell Stocks for October 14th - Zacks Investment Research
Celcuity Appoints David Gryska To Its Board Of Directors - The Manila Times
Why Celcuity Stock Was a Winner on Wednesday - The Motley Fool
Celcuity (NasdaqCM:CELC) Stock Forecast & Analyst Predictions - Simply Wall Street
Celcuity Inc.Common Stock (NQ: CELC - The Chronicle-Journal
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Transcript : Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com India
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com Canada
Celcuity (CELC) Institutional Ownership 2026 $CELC - MarketBeat
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com Canada
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com UK
Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
Celcuity To Participate in Upcoming Investor Conferences - Yahoo Finance
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - simplywall.st
What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Celcuity submits application for breast cancer drug expansion - Investing.com
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer - Yahoo Finance
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Australia
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com India
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com UK
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com India
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com India
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Celcuity Inc (CELC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celcuity Inc 주식 (CELC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Former 10% owner |
Jul 14 '26 |
Sale |
102.50 |
3,100,000 |
317,750,000 |
442,940 |
| 667, L.P. | Former Affiliate |
Jul 14 '26 |
Proposed Sale |
102.50 |
261,368 |
26,790,220 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Jul 14 '26 |
Proposed Sale |
102.50 |
2,838,632 |
290,959,780 |
0 |
| Laing Lance G. | Chief Science Officer |
Jun 02 '26 |
Option Exercise |
9.89 |
1,000 |
9,890 |
1,251,000 |
| Buller Richard E | Director |
May 04 '26 |
Proposed Sale |
140.46 |
6,000 |
842,788 |
0 |
| Buller Richard E | Director |
May 04 '26 |
Sale |
140.46 |
9,000 |
1,264,181 |
6,760 |
| Dalvey David | Director |
May 04 '26 |
Sale |
140.68 |
25,000 |
3,517,000 |
65,000 |
| Buller Richard E | Director |
May 04 '26 |
Option Exercise |
5.10 |
9,000 |
45,900 |
15,760 |
| Dalvey David | Director |
May 04 '26 |
Proposed Sale |
140.68 |
25,000 |
3,517,000 |
0 |
| Buller Richard E | Director |
Mar 31 '26 |
Proposed Sale |
110.27 |
6,000 |
661,607 |
0 |
5.11%
자본화:
|
볼륨(24시간):